EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

MetaNeb Versus Usual Care During Exacerbations of Cystic Fibrosis: An RCT

Naomi Chapman iD, Vinicius Cavalheri, Elizabeth F Smith, Jamie Wood, Luke W Garratt, Siobhain Mulrennan iD, Anne Smith, Anna S Tai, Kylie Hill iD

Respirology · 2025

DOI: 10.1111/resp.70092 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Respirology, 2025. Verfasst von Naomi Chapman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Curtin School of Allied Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Cystic Fibrosis, Respiratory Therapy. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institute for Respiratory Health, Curtin University, Cancer Council Western Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective During exacerbations, when symptom and treatment burden are increased, individuals with cystic fibrosis (CF) are likely to prefer airway clearance techniques (ACTs) that require minimal effort. Therefore, in adults with CF who were hospitalised with an exacerbation, we sought to compare the effect of the MetaNeb with usual ACTs on respiratory function and expectorated sputum.

Methods

This was a non‐blinded randomised controlled trial where adults hospitalised with a CF exacerbation were allocated to an experimental intervention (EIx; MetaNeb) or a control intervention (CIx; their usual ACT). Both groups underwent twice‐daily supervised airway clearance sessions, over an intervention period that ranged from 5 to 7 days during their hospitalisation. The primary outcome was ventilation inhomogeneity measured via lung clearance index (LCI) using the multiple breath washout technique. Secondary outcomes included adverse events, respiratory mechanics, forced expiratory volumes, sputum inflammatory markers, wellness, expectorated sputum, symptoms, participant satisfaction, and huff and cough counts.

Results

Thirty participants were randomised (EIx group n = 14; CIx group n = 16). On completion of the intervention period, there was a greater improvement in LCI following the EIx than CIx (mean difference −0.84 units [−1.66 to −0.02], as well as some measures of respiratory mechanics. There were no between‐group differences for the other secondary outcomes.

Conclusion

In adults with CF who were hospitalised with an exacerbation, twice daily MetaNeb produced greater improvements in ventilation inhomogeneity compared to twice daily usual ACTs. There were no between‐group differences shown for the other outcomes, including respiratory symptoms. Trial Registration Australian New Zealand Clinical Trials Registry (ACTRN12619001681145) image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisRespiratory TherapyHumansMaleFemaleAdultSputumForced Expiratory VolumeDisease ProgressionRespiratory Function TestsYoung AdultTreatment OutcomeHospitalization

Stichwörter der Autor:innen

airway clearance techniquescystic fibrosisphysiotherapy

Autor:innen und Institutionen

  • Curtin School of Allied Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia, Australia.
  • Physiotherapy Department, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
  • Institute for Respiratory Health, Perth, Western Australia, Australia.
  • Allied Health, South Metropolitan Health Service, Murdoch, Australia.
  • Wal-Yan Respiratory Research Centre, Telethon Kids Institute, Perth Children's Hospital, Perth, Western Australia, Australia.
  • Abilities Research Center, Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Naomi Chapman, Siobhain Mulrennan, Kylie Hill

Förderung

  • Institute for Respiratory Health
  • Curtin University
  • Cancer Council Western Australia
  • National Health and Medical Research Council (NHMRC)

Zitieren

APA

Chapman, N., Cavalheri, V., Smith, E. F., Wood, J., Garratt, L. W., Mulrennan, S., Smith, A., Tai, A. S., & Hill, K. (2025). MetaNeb Versus Usual Care During Exacerbations of Cystic Fibrosis: An RCT. Respirology. https://doi.org/10.1111/resp.70092

Vancouver

Chapman N, Cavalheri V, Smith EF, Wood J, Garratt LW, Mulrennan S, et al. MetaNeb Versus Usual Care During Exacerbations of Cystic Fibrosis: An RCT. Respirology. 2025. doi:10.1111/resp.70092

BibTeX
@article{Chapman2025,
  author = {Chapman, Naomi and Cavalheri, Vinicius and Smith, Elizabeth F and Wood, Jamie and Garratt, Luke W and Mulrennan, Siobhain and Smith, Anne and Tai, Anna S and Hill, Kylie},
  title = {MetaNeb Versus Usual Care During Exacerbations of Cystic Fibrosis: An RCT},
  journal = {Respirology},
  year = {2025},
  doi = {10.1111/resp.70092}
}
Kostenlos starten →